TCGA-33-AASL-01A-11R-A405-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.390
- KRAS_SIGNALING_DN+0.310
- PANCREAS_BETA_CELLS+0.260
- HEDGEHOG_SIGNALING+0.250
- APICAL_SURFACE+0.190
- OXIDATIVE_PHOSPHORYLATION+0.160
- UV_RESPONSE_UP+0.160
- G2M_CHECKPOINT+0.140
- SPERMATOGENESIS+0.140
- ESTROGEN_RESPONSE_LATE+0.120
Top 10 suppressed
- PROTEIN_SECRETION-0.450
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- ANDROGEN_RESPONSE-0.350
- TGF_BETA_SIGNALING-0.350
- HEME_METABOLISM-0.280
- MITOTIC_SPINDLE-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.230
- APOPTOSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.774 |
| 2 | 54f66d7c-b022-4df2-830d-48d55791c80e | — | — | 0.727 |
| 3 | TCGA-NC-A5HQ-01A-11R-A26W-07 | — | cohortSQ1 | 0.715 |
| 4 | C3N-03486 | — | cohortSQ1 | 0.705 |
| 5 | SRR1797265 | — | cohortSC | 0.698 |
| 6 | MNG40 | — | — | 0.698 |
| 7 | SRR12202495 | — | — | 0.692 |
| 8 | TCGA-UL-AAZ6-01A-11R-A41B-07 | — | B | 0.691 |
| 9 | SRR650144 | — | — | 0.688 |
| 10 | DRR168510 | — | — | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |